Abbott Laboratories (ABT) Gains from Sales and Divestitures (2010 - 2021)

Abbott Laboratories has disclosed Gains from Sales and Divestitures across 12 years of filings, most recently posting $6.5 million for Q4 2021.

• Gains from Sales and Divestitures for Q4 2021 came in at $6.5 million, down 9.21% year-over-year; the trailing twelve-month figure through Dec 2021 was $6.5 million (down 9.21% YoY), and the FY2021 annual result was $6.5 million, down 9.21% from the prior year.
• Gains from Sales and Divestitures came in at $6.5 million for Q4 2021 at Abbott Laboratories, down from $7.2 million in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $7.8 million in Q4 2019 to a low of $6.5 million in Q4 2021.
• The 5-year median for Gains from Sales and Divestitures is $7.5 million (2018), against an average of $7.3 million.
• Across the five-year window, Gains from Sales and Divestitures rose 29.29% in 2017 and fell 9.21% in 2021, its largest moves.
• Abbott Laboratories' Gains from Sales and Divestitures stood at $7.6 million in 2017, then dropped by 0.42% to $7.5 million in 2018, then grew by 3.03% to $7.8 million in 2019, then fell by 7.52% to $7.2 million in 2020, then fell by 9.21% to $6.5 million in 2021.
• The last three Gains from Sales and Divestitures figures came in at $6.5 million (Q4 2021), $7.2 million (Q4 2020), and $7.8 million (Q4 2019), per Business Quant data.